Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1964 1
1965 1
1970 2
1971 1
1973 3
1974 3
1975 4
1976 7
1977 7
1978 2
1979 2
1980 5
1981 8
1982 5
1983 9
1984 8
1985 9
1986 7
1987 3
1988 7
1989 6
1990 5
1991 3
1992 1
1993 5
1994 2
1995 5
1996 3
1997 5
1998 4
1999 7
2000 3
2001 2
2002 2
2003 8
2004 3
2005 5
2006 4
2007 9
2008 10
2009 16
2010 11
2011 18
2012 22
2013 26
2014 33
2015 45
2016 40
2017 50
2018 46
2019 54
2020 50
2021 65
2022 57
2023 32
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

689 results

Results by year

Filters applied: . Clear all
Page 1
Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.
Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M, Harder J, Arnold C, Gress T, Arnold R; PROMID Study Group. Rinke A, et al. J Clin Oncol. 2009 Oct 1;27(28):4656-63. doi: 10.1200/JCO.2009.22.8510. Epub 2009 Aug 24. J Clin Oncol. 2009. PMID: 19704057 Clinical Trial.
Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival.
Rinke A, Wittenberg M, Schade-Brittinger C, Aminossadati B, Ronicke E, Gress TM, Müller HH, Arnold R; PROMID Study Group. Rinke A, et al. Neuroendocrinology. 2017;104(1):26-32. doi: 10.1159/000443612. Epub 2016 Jan 6. Neuroendocrinology. 2017. PMID: 26731483 Free article. Clinical Trial.
EZH2 in Myeloid Malignancies.
Rinke J, Chase A, Cross NCP, Hochhaus A, Ernst T. Rinke J, et al. Cells. 2020 Jul 8;9(7):1639. doi: 10.3390/cells9071639. Cells. 2020. PMID: 32650416 Free PMC article. Review.
[Gastroenteropancreatic neuroendocrine tumors].
Breitling LP, Rinke A, Gress TM. Breitling LP, et al. Dtsch Med Wochenschr. 2019 Oct;144(21):1509-1521. doi: 10.1055/a-0865-0061. Epub 2019 Oct 21. Dtsch Med Wochenschr. 2019. PMID: 31634929 German.
Unmet Needs in Functional and Nonfunctional Pancreatic Neuroendocrine Neoplasms.
Jensen RT, Bodei L, Capdevila J, Couvelard A, Falconi M, Glasberg S, Kloppel G, Lamberts S, Peeters M, Rindi G, Rinke A, Rothmund M, Sundin A, Welin S, Fazio N; The ENETS 2016 Munich Advisory Board Participants; ENETS 2016 Munich Advisory Board Participants. Jensen RT, et al. Neuroendocrinology. 2019;108(1):26-36. doi: 10.1159/000494258. Epub 2018 Oct 3. Neuroendocrinology. 2019. PMID: 30282083 Free article. Review.
CML - Not only BCR-ABL1 matters.
Rinke J, Hochhaus A, Ernst T. Rinke J, et al. Best Pract Res Clin Haematol. 2020 Sep;33(3):101194. doi: 10.1016/j.beha.2020.101194. Epub 2020 Jun 7. Best Pract Res Clin Haematol. 2020. PMID: 33038988 Review.
Neuroendocrine tumours - Medical therapy: Biological.
Rinke A, Krug S. Rinke A, et al. Best Pract Res Clin Endocrinol Metab. 2016 Jan;30(1):79-91. doi: 10.1016/j.beem.2015.09.004. Epub 2015 Oct 9. Best Pract Res Clin Endocrinol Metab. 2016. PMID: 26971845 Review.
689 results